ArticleHeart rhythm O22025
Outcomes following catheter ablation for structural ventricular tachycardia stratified by left ventricular ejection fraction: A retrospective cohort study.
Article in Heart rhythm O2, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Despite advances in catheter ablation for ventricular tachycardia (VT), patients with lower left ventricular ejection fractions (LVEFs) tend to have worse outcomes. However, there is limited understanding of the periprocedural factors associated with recurrence, and whether LVEF directly influences outcomes. Objectives: The study sought to evaluate the electrophysiological characteristics and outcomes of patients undergoing VT ablation, stratified by LVEF. Methods: Adults (≥18 years of age) who underwent VT ablation at Mayo Clinic Rochester or Mayo Clinic Health System between January 1, 2012, and January 1, 2023, were included. Data were collected through chart review, and categorized by LVEF (<25%, 25%-49%, ≥50%). The primary outcome was VT recurrence. Logistic regression, robust linear regression, and survival analysis were utilized. Results: A total of 448 patients underwent 566 ablations. Significant differences were observed in VT recurrence at 1 year based on LVEF (<25%: 36.7%; 25%-49%: 32.3%; ≥50%: 22.2%; Conclusion: Lower LVEF was associated with higher VT recurrence, but after adjustment, this difference appeared to be driven by other factors, such as comorbid conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.